Lucille Markey Trust Sets Agenda For Going Out Of Business

Ever since 1983, when it was establisbed with a $300 million gift from the late Kentucky racehorse breeder Lucille P. Markey, the Markey trust has been sinking millions into basic biomedical research. At the same time the Miami-based endowment has been earning millions in interest on investments largely tied to oil properties. The net result: an enormous cash balance of close to $133 million—all of which must be given away over the next seven and one-half years, when, according to a con

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Ever since 1983, when it was establisbed with a $300 million gift from the late Kentucky racehorse breeder Lucille P. Markey, the Markey trust has been sinking millions into basic biomedical research. At the same time the Miami-based endowment has been earning millions in interest on investments largely tied to oil properties. The net result: an enormous cash balance of close to $133 million—all of which must be given away over the next seven and one-half years, when, according to a condition set forth in Mrs. Markey’s will, the trust will go out of the funding business permanently.

As the organization reaches the halfway mark on its way to the 1997 spending deadline, there has been talk that it may change course in the way it distributes its remaining wealth. Until now, Markey has concentrated almost exclusively on two funding programs: the prestigious Markey Scholar Awards; and the doling out ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Julia King

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo
Sapio Sciences logo

Sapio Sciences Introduces Biorepository Management Solution